Journal of surgical oncology · 2026
Contralateral Prophylactic Mastectomy at the Time of Therapeutic Mastectomy for Local Recurrence of Breast Cancer: Influence of Genetic Testing and Other Factors.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Santoro Candice N, Day Courtney N, Sturz-Ellis Jenna L, Hieken Tina J, Mrdutt Mary M
Аннотация
BACKGROUND AND OBJECTIVES: Surgical management of ipsilateral breast tumor recurrence (IBTR) is often mastectomy. No guidelines specifically address contralateral prophylactic mastectomy (CPM) for this population. We assessed factors associated with CPM at the time of IBTR mastectomy.
METHODS: Patients undergoing mastectomy for IBTR (10/2008-5/2024) were identified. Demographics, tumor characteristics, and treatment details were assessed.
RESULTS: Of the 381 eligible IBTR patients, 221 (58.0%) had a unilateral therapeutic mastectomy and 160 (42.0%) underwent mastectomy with CPM. CPM patients were younger (p < 0.0001), with lower clinical T category tumors (p < 0.001) and less HR + HER2- invasive disease (p = 0.004). CPM patients were more likely to undergo germline genetic testing (63.1% vs 41.6%, p < 0.0001) and were twice as likely to have immediate breast reconstruction (p < 0.0001). On multivariable analysis, younger age, HR-HER2 + IBTR subtype, pathogenic variants known at the time of surgery (relative to negative testing and/or no genetic testing), immediate breast reconstruction, and prior radiation for index cancer were each associated with CPM (all p < 0.05).
CONCLUSION: In our series of 381 patients treated with mastectomy for IBTR, 42% also had a CPM. Multiple factors, including age, tumor stage and biology, immediate breast reconstruction, and genetic testing may impact CPM choice.
METHODS: Patients undergoing mastectomy for IBTR (10/2008-5/2024) were identified. Demographics, tumor characteristics, and treatment details were assessed.
RESULTS: Of the 381 eligible IBTR patients, 221 (58.0%) had a unilateral therapeutic mastectomy and 160 (42.0%) underwent mastectomy with CPM. CPM patients were younger (p < 0.0001), with lower clinical T category tumors (p < 0.001) and less HR + HER2- invasive disease (p = 0.004). CPM patients were more likely to undergo germline genetic testing (63.1% vs 41.6%, p < 0.0001) and were twice as likely to have immediate breast reconstruction (p < 0.0001). On multivariable analysis, younger age, HR-HER2 + IBTR subtype, pathogenic variants known at the time of surgery (relative to negative testing and/or no genetic testing), immediate breast reconstruction, and prior radiation for index cancer were each associated with CPM (all p < 0.05).
CONCLUSION: In our series of 381 patients treated with mastectomy for IBTR, 42% also had a CPM. Multiple factors, including age, tumor stage and biology, immediate breast reconstruction, and genetic testing may impact CPM choice.